PDGFRB (Ab-751) Antibody

What is PDGFRB and what is the significance of phosphorylation at Y751?

PDGFRB is a receptor tyrosine kinase belonging to the class III subfamily of receptor tyrosine kinases (RTKs). It plays essential roles in cell proliferation, survival, differentiation, chemotaxis, and migration. The phosphorylation at tyrosine 751 (Y751) is a key activation event in PDGFRB signaling pathways, particularly after binding with PDGF-BB ligand. This phosphorylation site serves as a critical docking site for downstream effector molecules, making it an important target for studying PDGFRB-mediated signaling . The tyrosine residue at position 751 is conserved across species, including humans, mice, and rats, highlighting its evolutionary importance in PDGFRB function .

What are the common applications for PDGFRB (Ab-751) antibodies?

PDGFRB (Ab-751) antibodies are versatile tools that can be utilized in multiple experimental approaches:

• Western blotting (WB): For detecting phosphorylated PDGFRB in cell or tissue lysates, typically appearing at approximately 190-240 kDa depending on the experimental system .

• Immunohistochemistry (IHC): For visualizing phosphorylated PDGFRB in paraffin-embedded or frozen tissue sections .

• Immunocytochemistry (ICC): For examining subcellular localization of phosphorylated PDGFRB in cultured cells .

• ELISA: For quantitative detection of phosphorylated PDGFRB in various sample types .

The optimal application depends on your specific research question and experimental design.

Which cell lines are commonly used as positive controls for PDGFRB (Ab-751) antibody validation?

Several cell lines have been validated as positive controls for testing PDGFRB (Ab-751) antibodies:

• CCD-1070Sk human foreskin fibroblast cells: Show strong phosphorylation of PDGFRB at Y751 when stimulated with PDGF-BB .

• NIH-3T3 mouse embryonic fibroblast cells: Demonstrate robust phosphorylation at Y751 upon PDGF-BB treatment .

• BJ human skin fibroblast cells: Display strong immunofluorescence signal when stimulated with PDGF-BB .

For maximum phosphorylation signal, cells should be treated with 100 ng/mL of recombinant human PDGF-BB for approximately 20 minutes before harvesting for analysis .

What is the recommended storage and handling procedure for PDGFRB (Ab-751) antibodies?

Proper storage and handling are crucial for maintaining antibody performance:

• Long-term storage: Store at -20°C to -70°C for up to 12 months from the date of receipt .

• Short-term storage: For frequent use, store at 4°C for up to one month .

• Working solutions: After reconstitution, antibodies can be stored at 2-8°C for approximately 1 month under sterile conditions .

• Avoid repeated freeze-thaw cycles as they can degrade the antibody and reduce its effectiveness .

When handling, always use sterile technique and appropriate personal protective equipment to prevent contamination and degradation of the antibody.

How can I optimize Western blot conditions for detecting phospho-PDGFRB (Y751) in different tissue samples?

Optimizing Western blot conditions for phospho-PDGFRB detection requires careful consideration of several parameters:

• Lysis buffer selection: Use buffers containing phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) to preserve phosphorylation status. RIPA or NP-40 based buffers with 1-2% SDS work well for membrane proteins like PDGFRB .

• Sample preparation:

  • Process tissues rapidly after collection to minimize dephosphorylation

  • Maintain samples at 4°C during processing

  • Use reducing conditions during sample preparation

• Gel selection and transfer conditions:

  • Use lower percentage gels (6-8%) for better resolution of high molecular weight PDGFRB (190-240 kDa)

  • Extend transfer time for large proteins (overnight at low amperage recommended)

  • Consider wet transfer systems for more efficient transfer of large proteins

• Antibody dilution: Start with 1:500-1:1000 dilution for Western blotting applications and optimize as needed .

• Signal detection: Use sensitive chemiluminescent substrates for detecting potentially low abundance phosphorylated species.

What are the potential cross-reactivity issues with PDGFRB (Ab-751) antibodies and how can these be minimized?

Cross-reactivity considerations are critical for accurate experimental interpretation:

• Potential cross-reactivity sources:

  • Other phosphorylated RTKs with similar sequence homology around Y751

  • Non-specific binding to other phosphotyrosine-containing proteins

  • Cross-reactivity with unphosphorylated PDGFRB

• Minimization strategies:

  • Include appropriate negative controls (untreated cells, phosphatase-treated lysates)

  • Use blocking peptides specific to the phosphorylated epitope

  • Validate specificity through multiple techniques (WB, IP followed by WB)

  • Compare results with multiple antibodies targeting the same phosphorylation site

  • Employ genetic approaches (siRNA knockdown, CRISPR knockout) to confirm specificity

• Validation approach: Western blot analysis should show a significant increase in signal intensity after PDGF-BB stimulation compared to unstimulated samples, with minimal background in unstimulated samples .

How can I differentiate between PDGFR alpha and PDGFR beta phosphorylation in complex tissue samples?

Differentiating between the phosphorylation status of PDGFR alpha and PDGFR beta requires careful experimental design:

• Molecular weight discrimination: PDGFR beta appears at approximately 190-240 kDa while PDGFR alpha typically runs slightly lower at approximately 170-180 kDa on SDS-PAGE gels .

• Sequential immunoprecipitation approach:

  • First immunoprecipitate with isoform-specific antibodies (anti-PDGFR alpha or anti-PDGFR beta)

  • Then probe with phospho-specific antibodies to detect phosphorylation status

• Phosphorylation site specificity:

  • Use antibodies targeting unique phosphorylation sites in each receptor

  • The Y751 site in PDGFR beta differs from corresponding sites in PDGFR alpha

• Genetic models:

  • Use cell lines or tissues with selective knockdown/knockout of either receptor

  • Compare phosphorylation patterns with wild-type samples

• Ligand selectivity:

  • PDGF-BB activates both receptors, while PDGF-AA selectively activates PDGFR alpha

  • Use selective ligands to discriminate between receptor activation patterns

What are the key considerations for quantifying PDGFRB phosphorylation in signaling pathway analysis?

Accurate quantification of PDGFRB phosphorylation requires attention to several methodological details:

• Normalization strategies:

  • Normalize phospho-PDGFRB signal to total PDGFRB levels

  • Use loading controls (β-actin, GAPDH) for general protein normalization

  • Consider normalization to unstimulated control samples

• Temporal dynamics:

  • PDGFRB phosphorylation at Y751 typically peaks at 15-20 minutes post-stimulation

  • Design time-course experiments to capture transient phosphorylation events

• Dose-response relationships:

  • PDGF-BB concentration should be optimized (typically 50-100 ng/mL)

  • Consider testing multiple concentrations to establish dose-response curves

• Quantification methods:

  • Densitometry analysis of Western blots

  • ELISA-based phosphorylation assays

  • Phospho-flow cytometry for single-cell resolution

  • Consider multiplexed approaches to simultaneously measure multiple phosphorylation sites

• Statistical considerations:

  • Perform experiments in biological triplicates

  • Apply appropriate statistical tests for comparative analyses

  • Consider variability in baseline phosphorylation across cell types and tissues

How should I design experiments to study the interaction between phosphorylated PDGFRB (Y751) and downstream signaling molecules?

Designing experiments to study interactions between phosphorylated PDGFRB (Y751) and downstream effectors requires multiple complementary approaches:

• Co-immunoprecipitation (Co-IP) strategy:

  • Immunoprecipitate with anti-phospho-PDGFRB (Y751) antibody

  • Probe for known downstream effectors (PI3K, SHP2, Src)

  • Alternatively, immunoprecipitate with antibodies against effector proteins and probe for phospho-PDGFRB

  • Use mild lysis conditions to preserve protein-protein interactions

• Proximity ligation assay (PLA):

  • Visualize direct protein-protein interactions in situ

  • Combine anti-phospho-PDGFRB (Y751) with antibodies against downstream effectors

  • Provides spatial information about interaction sites within cells

• Phosphorylation kinetics correlation:

  • Perform time-course analysis of PDGFRB Y751 phosphorylation

  • Simultaneously monitor phosphorylation of downstream substrates

  • Correlate temporal patterns to establish signaling hierarchies

• Pharmacological inhibition:

  • Use selective inhibitors of PDGFRB kinase activity

  • Monitor effects on downstream signaling events

  • Compare with effects of mutations at the Y751 site

• Functional mutation analysis:

  • Generate Y751F mutants to prevent phosphorylation at this site

  • Compare signaling outcomes with wild-type receptor

  • Use reconstitution experiments in knockout systems

What controls should be included when validating a new lot of PDGFRB (Ab-751) antibody?

Comprehensive validation of new antibody lots is essential for experimental reliability:

• Positive controls:

  • Cell lines known to express PDGFRB (fibroblasts, smooth muscle cells)

  • Paired stimulated (+PDGF-BB) and unstimulated samples

  • Recombinant phosphorylated peptides containing the Y751 sequence

• Negative controls:

  • Cell lines with low/no PDGFRB expression

  • Samples treated with phosphatase to remove phosphorylation

  • Y751F mutant PDGFRB-expressing cells

  • PDGFRB knockout/knockdown samples

• Cross-lot comparison:

  • Compare new lot performance with previously validated lots

  • Assess consistency in band intensity, specificity, and background

  • Document lot-to-lot variation for future reference

• Multi-technique validation:

  • Test antibody performance in all intended applications (WB, IHC, ICC)

  • Compare results across techniques for consistency

  • Optimize dilutions for each application independently

• Peptide competition:

  • Pre-incubate antibody with phosphorylated and non-phosphorylated peptides

  • Specific signal should be blocked by phosphorylated peptide but not by non-phosphorylated version

How can I optimize immunohistochemistry protocols for detecting phospho-PDGFRB (Y751) in different tissue types?

Optimizing IHC protocols for phospho-PDGFRB detection requires tissue-specific considerations:

• Tissue fixation and preservation:

  • Use fresh tissues when possible

  • Fix tissues rapidly (within minutes of collection)

  • Consider phosphatase inhibitors in fixation buffers

  • Optimize fixation time to balance antigen preservation and tissue morphology

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Test multiple antigen retrieval conditions to optimize signal-to-noise ratio

  • Adjust retrieval times based on tissue type and thickness

• Blocking and antibody dilution:

  • Use 5-10% normal serum from the same species as the secondary antibody

  • Include phosphatase inhibitors in antibody diluent

  • Start with manufacturer-recommended dilutions (typically 1:50-1:200 for IHC) and optimize

  • Consider overnight incubation at 4°C for improved sensitivity

• Detection systems:

  • Polymer-based detection systems often provide better sensitivity for phospho-epitopes

  • Consider tyramide signal amplification for low-abundance phospho-proteins

  • Use fluorescent secondary antibodies for co-localization studies

• Counterstaining considerations:

  • Select counterstains that don't obscure the phospho-PDGFRB signal

  • Consider nuclear counterstains (DAPI, hematoxylin) for cellular context

What are the best practices for using phospho-PDGFRB (Y751) antibody in multiplexed immunofluorescence studies?

Multiplexed immunofluorescence with phospho-PDGFRB antibodies requires careful planning:

• Antibody compatibility:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • If using multiple rabbit antibodies, consider sequential staining with stripping between rounds

  • Test each antibody individually before combining in multiplexed protocols

• Spectral considerations:

  • Choose fluorophores with minimal spectral overlap

  • Include single-stained controls for spectral unmixing

  • Consider brightness differences when selecting fluorophores for low-abundance targets

• Signal amplification strategies:

  • Use tyramide signal amplification for phospho-epitopes

  • Consider quantum dots for enhanced stability and brightness

  • Balance amplification with potential background increase

• Staining sequence optimization:

  • Apply phospho-specific antibodies first when possible

  • Consider the impact of antigen retrieval on epitope availability

  • Test different staining sequences to determine optimal order

• Validation approaches:

  • Include samples with known phosphorylation status

  • Compare staining patterns with single-plex experiments

  • Use pharmacological inhibitors to confirm signal specificity

How can I address weak or inconsistent phospho-PDGFRB (Y751) signals in Western blot experiments?

Troubleshooting weak phospho-PDGFRB signals requires systematic evaluation of multiple factors:

• Sample preparation improvements:

  • Ensure rapid sample processing to minimize dephosphorylation

  • Increase phosphatase inhibitor concentration in lysis buffers

  • Consider phosphatase inhibitor cocktails containing sodium orthovanadate, sodium fluoride, and sodium pyrophosphate

  • Maintain samples at 4°C throughout processing

• Technical optimization:

  • Increase protein loading (start with 50-100 μg total protein)

  • Optimize primary antibody concentration and incubation conditions

  • Extend primary antibody incubation time (overnight at 4°C)

  • Try different membrane types (PVDF often performs better than nitrocellulose for phospho-epitopes)

  • Use high-sensitivity detection reagents

• Stimulation protocol refinement:

  • Verify PDGF-BB activity with a functional assay

  • Optimize stimulation time (typically 15-20 minutes for peak Y751 phosphorylation)

  • Ensure cells are properly serum-starved before stimulation

  • Test different PDGF-BB concentrations (50-100 ng/mL is typically optimal)

• Signal enhancement strategies:

  • Consider immunoprecipitation before Western blotting to concentrate the target protein

  • Use enhanced chemiluminescence substrates designed for low-abundance proteins

  • Try fluorescent secondary antibodies with digital imaging systems

What experimental factors might affect the interpretation of phospho-PDGFRB (Y751) data in different research contexts?

Several factors can impact the interpretation of phospho-PDGFRB experimental results:

How can I distinguish between specific phospho-PDGFRB (Y751) signal and background in immunofluorescence studies?

Differentiating specific signal from background in immunofluorescence requires rigorous controls and optimization:

• Essential controls:

  • Unstimulated cells (minimal phosphorylation expected)

  • PDGF-BB stimulated cells (positive control)

  • Secondary antibody-only control (to assess non-specific binding)

  • Peptide competition control (specific signal should be blocked)

  • Phosphatase-treated samples (to confirm phospho-specificity)

• Pattern analysis:

  • Genuine phospho-PDGFRB signal should localize to cell membranes and cytoplasm

  • Signal should increase upon PDGF-BB stimulation

  • Cell surface staining should be evident in stimulated samples

  • Non-specific nuclear staining often indicates background issues

• Optimization approaches:

  • Adjust fixation protocol (paraformaldehyde concentration, fixation time)

  • Optimize permeabilization (type and duration)

  • Test different blocking reagents (BSA, normal serum, commercial blockers)

  • Adjust antibody concentration and incubation conditions

  • Modify washing steps (duration, buffer composition)

• Advanced validation:

  • Co-staining with total PDGFRB antibody to confirm localization

  • siRNA knockdown of PDGFRB to confirm specificity

  • Parallel Western blot analysis to corroborate immunofluorescence findings

How can phospho-PDGFRB (Y751) antibodies be utilized in patient-derived samples for translational research?

Applications of phospho-PDGFRB antibodies in translational research contexts:

• Tissue microarray (TMA) analysis:

  • Screen multiple patient samples simultaneously

  • Correlate phosphorylation status with clinical parameters

  • Identify potential biomarker applications

  • Standardize staining protocols for clinical compatibility

• Liquid biopsy applications:

  • Detect phospho-PDGFRB in circulating tumor cells

  • Monitor treatment response through phosphorylation changes

  • Develop sensitive ELISA or bead-based assays for serum/plasma

• Patient-derived xenograft (PDX) models:

  • Assess phosphorylation status before and after treatment

  • Correlate phosphorylation with drug response

  • Monitor changes in signaling during disease progression

• Ex vivo tissue culture systems:

  • Expose patient tissue to PDGFR-targeted therapies

  • Monitor phosphorylation changes as predictors of response

  • Develop personalized medicine approaches

• Companion diagnostic potential:

  • Standardize phospho-PDGFRB detection for clinical applications

  • Correlate phosphorylation status with response to kinase inhibitors

  • Develop quantitative scoring systems for clinical implementation

What emerging technologies might enhance the detection and analysis of PDGFRB phosphorylation at Y751?

Emerging technologies with potential applications in phospho-PDGFRB research:

• Mass spectrometry-based approaches:

  • Targeted mass spectrometry for absolute quantification

  • Phosphoproteomics for comprehensive pathway analysis

  • MALDI imaging mass spectrometry for spatial distribution in tissues

• Single-cell analysis techniques:

  • Single-cell Western blotting

  • Mass cytometry (CyTOF) for multi-parameter analysis

  • Single-cell RNA-seq paired with protein analysis

• Advanced imaging methods:

  • Super-resolution microscopy for nanoscale localization

  • Intravital microscopy for in vivo phosphorylation dynamics

  • Label-free imaging techniques

• Biosensor technologies:

  • FRET-based sensors for real-time phosphorylation monitoring

  • Nanobody-based detection systems

  • Aptamer-based recognition elements

• Computational approaches:

  • Machine learning for image analysis and pattern recognition

  • Integrative multi-omics data analysis

  • Predictive modeling of phosphorylation dynamics